VCs led by HBM, Samsara back single-asset Mitsubishi Tanabe spinout Mineralys with $40M for hypertension program

A VC syndicate led by HBM and Samsara will supply newly launched Mineralys with $40 million in series A funding to run a Phase II trial of an aldosterone synthase inhibitor to treat hypertension, giving the candidate a new life outside of Mitsubishi Tanabe.

Philadelphia-based Mineralys Therapeutics Inc. is preparing to start a Phase II dose-finding and proof-of-concept trial this quarter of ALDOS inhibitor MLS-101. CEO Jon Congleton told BioCentury data on the primary endpoint, measuring reductions in systolic blood pressure, will be due in 2H22...